PTO/SB/17 (10-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
o a collection of information upless it disables a valid OMB.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERC er the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

F	EE TRANSMITTAL
	for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 180.00

CLIMAGE

espond to a conjection or mic	official diffess it displays a valid offic defice from
Co	omplete if Known
Application Number	10/657,045
Filing Date	September 4, 2003
First Named Inventor	Tedeschi et al.
Examiner Name	Fubara, Blessing M.
Art Unit	1615
Attorney Docket No.	P297CON2 (51288-0061US)

METHOD OF PAYMENT (check all that apply) FEE CALCULATION (continued)					
✓ Check Credit card Money Other None	3. AD	DITIO	NAL FEES		
✓ Order ☐ Order ☐ Order ☐ Order			Small Entity		
Donosit			ee Fee Fee Description	Fee Paid	
Account 50-3207	1051	130	051 65 Surcharge - late filing fee or oath		
Number Deposit	1052	50	2052 25 Surcharge - late provisional filing fee or		
Account Name	1053	130	cover sheet 1053 130 Non-English specification		
The Director is authorized to: (check all that apply)	1812		812 2,520 For filing a request for ex parte reexamination		
Charge fee(s) indicated below Credit any overpayments	1804	920*	1804 920* Requesting publication of SIR prior to		
Charge any additional fee(s) or any underpayment of fee(s)			Examiner action		
Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.	1805	1,840"	1805 1,840* Requesting publication of SIR after Examiner action		
FEE CALCULATION	1251	110	2251 55 Extension for reply within first month		
1. BASIC FILING FEE	1252	420	2252 210 Extension for reply within second month		
Large Entity Small Entity	1253	950	2253 475 Extension for reply within third month		
Fee Fee Fee Fee Fee Description Fee Paid Code (\$) Code (\$)	1254	1,480	2254 740 Extension for reply within fourth month	 	
1001 770 2001 385 Utility filing fee	1255	2,010	2255 1,005 Extension for reply within fifth month		
1002 340 2002 170 Design filing fee	1401	330	2401 165 Notice of Appeal	<u> </u>	
1003 530 2003 265 Plant filing fee	1402	330	2402 165 Filing a brief in support of an appeal		
1004 770 2004 385 Reissue filing fee	1403	290	2403 145 Request for oral hearing	$\vdash \vdash \vdash$	
1005 160 2005 80 Provisional filing fee	1451	1,510	1451 1,510 Petition to institute a public use proceeding		
SUBTOTAL (1) (\$) 0	1452	110	2452 55 Petition to revive - unavoidable		
2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE	1453	1,330	2453 665 Petition to revive - unintentional		
Fee from	1501	•	2501 665 Utility issue fee (or reissue)	\vdash	
Extra Claims below Fee Paid Total Claims X = X	1502	480	2502 240 Design issue fee 2503 320 Plant issue fee		
Independent 3** = X	1503	640 130	1460 130 Petitions to the Commissioner		
Claims Multiple Dependent	1460	50	1807 50 Processing fee under 37 CFR 1.17(q)		
Large Entity Small Entity	1807	180	1806 180 Submission of Information Disclosure Stmt	180.00	
Fee Fee Fee Fee Description	1806		Recording each patent assignment per		
Code (\$) Code (\$) 1202 18 2202 9 Claims in excess of 20	8021	40	property (times number of properties)		
1202 18 2202 9 Claims in excess of 20 1201 86 2201 43 Independent claims in excess of 3	1809	770	2809 385 Filing a submission after final rejection (37 CFR 1.129(a))		
1203 290 2203 145 Multiple dependent claim, if not paid	1810	770	2810 385 For each additional invention to be		
1204 86 2204 43 ** Reissue independent claims			examined (37 CFR 1.129(b))		
over original patent	1801		2801 385 Request for Continued Examination (RCE)		
1205 18 2205 9 ** Reissue claims in excess of 20 and over original patent	1802	900	1802 900 Request for expedited examination of a design application		
[40.0		fee (sp			
**or number previously paid, if greater; For Reissues, see above	*Redu	uced by	Basic Filing Fee Paid SUBTOTAL (3) (\$) 180.	00	
(Complete (if applicable))					

SUBMITTED BY

Name (Print/Type)

Louis C. (Englistration No. (Attornev/Agent)

Signature

Registration No. (Attornev/Agent)

39,645

Telephone 949-253-0900

Date

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ttached or enclosed) is being depo

PATENT

Attorney Docket No.: P297CON2 (51288-00061 US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

policant:

Tedeschi et al.

Serial No.:

10/657,045

Filed:

September 4, 2003

Title:

USES FOR MEDICAL DEVICES HAVING

A LUBRICIOUS, NITRIC OXIDE-

RELEASING COATING

Conf. No.:

1082

Examiner:

Blessing M. Fubara

Art Unit:

1615

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §§ 1.56. 1.97 AND 1.98

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. §§ 1.56. 1.97 and 1.98, and in accordance with the provisions in the Manual of Patent Examining Procedure §§609 and 707.05(b), enclosed is a copy of the substitute for FORM PTO-1449 listing the references that are known to applicant. Applicants enclose copies of each of the listed references which are not U.S. patents.

This art is being filed for consideration in compliance with § 1.97 within the following time period:

In accordance with 37 C.F.R. § 1.97 (c) This information is being filed for consideration and entry after the period specified in paragraph 37 C.F.R. § 1.97(b), but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application.

Applicants enclose the fee of \$180.00 as set forth in § 1.17(p).

The submission of the above-described documents does not constitute an admission nor should it be construed as a representation that: a search has been made, or that it is material to patentability as defined in § 1.56(b).

Applicant reserves the right to antedate or otherwise remove the documents as references.

Page 2 of 2

It is respectfully requested that the listed references be considered in the examination of this application and identified on the list of references cited on the patent issuing for this application. Applicant also requests that an initialed copy of the substitute for FORM PTO-1449 be entered in the application file and returned to applicant with the next communication from the Office in accordance with MPEP § 609.

The Examiner is invited to contact the undersigned by telephone if it is felt that a telephone interview would advance the prosecution of the present application. The Director is hereby authorized to charge any fees or credit any overpayments to Deposit Account No. 50-3207 associated with this response.

By:

Respectfully submitted,

PRESTON GATES & ELLIS, LLP

Date

Contact information below for inquiries regarding the above submission:

Customer No.: 28,390 Louis C. Cullman Preston Gates Ellis LLP (949) 253-0900 Telephone (949) 253-0902 Fax Attorney for Applicant Registration No. 39,645

OUIS CULLMAN

Enclosures: PTO-1440 and References cited thereon, check in the amount of \$180.00, Amendment, Application Data Sheet and Transmittal.

Modified version which contains information viewed on PTO/SB/08A (08-03) which has been proved for use through 07/31/2006. OMB 0651-0031 This is a substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPEICANTS

(use as many sheets as necessary)

Application Number 10/657,045

Filing Date 09/04/03

First Named Inventor Tedeschi et al.

Group Art Unit 1615

Examiner Name Fubara, Blessing M.

Attorney Docket Number P297CON2 (51288-00061US)

Sheet 1 of 4 AUG 1 6 2004

		TADEUS. P	ATENT DOCUMENTS			
EXAMINER	DOCUMENT	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
INITIALS	NUMBER 4,373,009	02/08/83	Winn	428	424.2	
	4,585,666	04/29/86	Lambert	427	2	<u> </u>
	4,625,012	11/25/86	Rizk et al.	528	28	
	4,894,231	01/16/90	Moreau et al.	424	426	
	5,032,666	07/16/91	Hu et al.	528	70	
	5,040,544	08/20/91	Lessar et al.	607	122	<u> </u>
	5,134,192	07/28/92	Feijen et al.	525	54.1	
	5,171,217	12/15/91	March et al.	604	507	***
	5,380,299	01/10/95	Fearnot et al.	604	265	······································
	5,383,928	01/10/95	Scott et al.	623	1.12	
	5,447,724	09/05/95	Heimus et al.	424	426	
		11/07/95	Berg et al.	427	2.3	
	5,464,650	11/07/93	Lindall	604	20	
	5,470,307	04/30/96	Domb et al.	604	265	
	5,512,055	06/11/96	Whitbourne et al.	424	423	
	5,525,348	09/10/96	Dinh et al.	600	36	
	5,554,182		Lambert	424	486	<u> </u>
	5,562,922	10/08/96	Crocker	604	103.01	
	5,571,089	11/05/96	Dinh et al.	623	1.22	
	5,591,227	01/07/97		424	423	
	5,605,696	02/25/97	Eury et al. Fearnot et al.	623	1.42	
	5,609,629	03/11/97		424	426	
	5,612,052	03/18/97	Shalaby	604	265	
	5,624,411	04/29/97	Tuch		1.42	
	5,637,113	06/10/97	Tartaglia et al.	623 428	334	
	5,645,931	07/08/97	Fan et al.		2.24	
	5,660,873	08/26/97	Nikolaychik et al.	427		
	5,662,960	09/02/97	Hostettler et al.	427	2.3	
	5,674,192	10/07/97	Sahatjian et al.	604		
	5,683,451	11/04/97	Lenker et al.	623	1.11	
	5,698,738	12/16/97	Garfield et al.	564	112	
	5,700,286	12/23/97	Tartaglia et al.	623	1.15	
	5,702,754	12/30/97	Zhong	427	2.12	
	5,705,583	01/06/98	Bowers et al.	526	277	
	5,756,145	05/26/98	Darouiche	427	2.24	
	5,756,553	05/26/98	Iguchi et al.	514	772.3	<u> </u>

EXAMINER SIGNATURE DATE CONSIDERED

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 2213-1450. If you need assistance in completing the form, call 1-800-PTO-9199 pl (1-800-786-9199) and select option 2. The Applicant's unique catalion designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document. by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

Modified version which contains information viewed on PTO/SB/08A (08-03) which has been proved for use through 07/31/2006. OMB 0651-0031 This is a substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 4

Application Number	10/657,045
Filing Date	09/04/03
First Named Inventor	Tedeschi et al.
Group Art Unit	1615
Examiner Name	Fubara, Blessing M.
Attorney Docket Number	P297CON2 (51288-00061US)

5,762,944	06/09/98	Inoue et al.	424	400
5,770,229	06/23/98	Tanihara et al.	424	488
5,776,611	07/07/98	Elton et al.	428	423.1
5,792,106	08/11/98	Mische	604	103.01
5,797,887	08/25/98	Rosen et al.	604	265
5,824,049	10/20/98	Ragheb et al.	623	1.44
5,824,054	10/20/98	Khosravi et al.	623	1.44
5,843,120	12/01/98	Israel et al.	523	1.15
5,843,166	12/01/98	Lentz et al.	623	1.13
	12/01/98	Yan	623	1.42
5,843,172	12/15/98	Hostettler et al.	427	536
5,849,368	12/29/98	Darouiche	424	423
5,853,745	02/09/99	Zhong	427	2.12
5,869,127	02/09/99	Ragheb et al.	623	1.13
5,873,904	04/06/99	Leone et al.	604	264
5,891,108	04/06/99	Lambert	424	429
5,900,246		Hostettler et al.	428	424.8
5,919,570	07/06/99		623	1.42
5,972,027	10/26/99	Johnson	604	265
5,997,517	12/07/99	Whitebourne	606	191
6,024,763	02/15/00	Lenker et al.	623	1.11
6,048,360	04/11/00	Khosravi et al.		277
6,090,901	07/18/00	Bowers et al.	526	
6,096,070	08/01/00	Ragheb et al.	623	1.39
6,153,252	11/28/00	Hossainy et al.	427	2.3
6,156,345	12/05/00	Chudzik et al.	424	485
6,197,051	03/06/01	Zhong	623	1.46
6,214,901	04/10/01	Chudzik et al.	523	113
6,254,632	07/03/01	Wu et al.	623	1.15
6,258,121	07/10/01	Yang et al.	623	1.46
6,287,285	09/11/01	Michal et al.	604	264
6,299,604	10/09/01	Ragheb et al.	604	265
6,306,176	10/23/01	Whitbourne	623	23.59
6,344,035	02/05/02	Chudzik et al.	604	265
6,355,060	03/12/02	Lenker et al.	623	1.34
6,379,382	04/30/02	Yang	623	1.42
6,451,050	09/17/02	Rudakov et al.	623	1.15
6,451,373	09/17/02	Hossainy et al.	427	2.25

EXAMINER	DATE
SIGNATURE	CONSIDERED
	at a self-self-base file found by the file

This cotlection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, V.A 22313-1450. If you need assistance in completing the form, cair 1-800-PTO-9199 (1-800-786-9199) and select option 2. EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered, include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japaneses patent documents, the indication of the year of the reign of the Emperor must precode the serial number of the patent document. 5Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible, 6 Applicant is to place a check mark here if English language Translation is attached.

Modified version which contains information viewed on PTO/SB/08A (08-03) which has been proved for use through 07/31/2006. OMB 0651-0031

This is a substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 4

Application Number	10/657,045
Filing Date	09/04/03
First Named Inventor	Tedeschi et al.
Group Art Unit	1615
Examiner Name	Fubara, Blessing M.
Attorney Docket Number	P297CON2 (51288-00061US)

	6,458,152	10/01/02	Khosravi et al.	623	1.13	
	6,488,701	12/03/02	Nolting et al.	623	1.13	
	6,506,437	01/14/03	Harish et al.	427	2.25	
ļ — — — — — — — — — — — — — — — — — — —	6,547,814	04/15/03	Edwin et al.	623	1.13	

FOREIGN PATENT DOCUMENTS							
EXAMINER INITIALS	DOCUMENT NUMBER	PUBLICATION DATE	COUNTRY OR PATENT OFFICE	CLASS	SUBCLASS	TRANS YES	LATION NO
	357401B1	3/90	EP			X	
	352295 B1	6/93	EP			X	
	397784 B1	10/93	EP			X	<u> </u>

	OTHER DOCUMENTS			
EXAMINER INITIALS	Include name of the author (in CAPITAL LETTERS), title of the article, title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
HTTTALS	Adams et al., "Inhibition of Nitric Oxide Synthase Disrupts Inhibitory Gating of Auditory Responses in Rat Hippocampus," The Journal of Pharmacology and Experimental Therapeutics, 287:760-5 (November 1998)			
******	Berkenbosch et al., "Management of Postoperative Chylothorax with Nitric Oxide: A Case Report," Critical Care Medicine, 27:1022-4 (May 1999)			
1	Carrier et al., "Nitric Oxide Inhalation in the Treatment of Primary Graft Failure Following Heart Transplantation," The Journal of Heart and Lung Transplantation, 18:664-7 (July 1999)			
Cooper et al., "Transient Loss of Resistance to Pulmonary Tuberculosis in p47PHOX-/-Mice," Ir and Immunity, 68:1231-4 (March 2000)				
	El-Haddad et al., "Nitric Oxide Modulates Spontaneous Swallowing Behaviour in Near-Term Ovine Fetus." American Journal of Physiology, 277:R981-6 (October 1999)			
	Freedman, et al., "Acute Effect of Nitric Oxide on Raynaud's Phenomenon in Scleroderma," The Lancet, 354:739 (August 1999)			
	Goodwin et al., "Favorable Response of Eisenmenger Syndrome to Inhaled Nitric Oxide During Pregnancy," American Journal of Obstetrics and Gynecology, 180:64-7 (January 1999)			
	Gradini et al., "Nitric Oxide Synthases in Normal and Benign Hyperplastic Human Prostate: Immunohistochemistry and Molecular Biology," Journal of Pathology, 189:224-9 (October 1999)			
	Holopainen et al., "Nitric Oxide Inhalation Inhibits Pulmonary Apoptosis but not Inflammatory Injury in Porcine Meconium Aspiration," Acta Paediatrica, 88:1147-55 (October 1999)			
	Ishihara et al., "Inhaled Nitric Oxide Prevents Left Ventricular Impairment During Endotoxemia," Journal of Applied Physiology, 85:2018-24 (December 1998)			

EXAMINER	DATE
SIGNATURE	CONSIDERED

SIGNATURE

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. OR NOT SEND PEES OF COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, I/y oneed assistance in completing the form, call 1-800-PTO-9199 (1-800-97-

Modified version which contains information viewed on PTO/SB/08A (08-03) which has been proved for use through 07/31/2006. OMB 0651-0031 This is a substitute for form 1449/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 4

Application Number	10/657,045
Filing Date	09/04/03
First Named Inventor	Tedeschi et al.
Group Art Unit	1615
Examiner Name	Fubara, Blessing M.
Attorney Docket Number	P297CON2 (51288-00061US)

Jacobs et al., "Aerosolized Soluble Nitric Oxide Donor Improves Oxygenation and Pulmonary Hypertension in Acute Lung Injury," American Journal of Respiratory and Critical Care Medicine, 158:1536-42 (November 1998)
Kiris et al., "Reversal of Cerebral Vasospasm by the Nitric Oxide Donor SNAP in an Experimental Model of Subarachnoid Haemorrhage," Acta Neurochirurgica, 141:1323-9 (1999)
Lambermont et al., "Effects of Inhaled Nitric Oxide on Pulmonary Hemodynamics in a Porcine Model of Endotoxin Shock." Critical Care Medicine, 27:1953-7 (September 1999)
Lewis et al., "Nitric Acid Limits the Eicosanoid-Dependant Bronchoconstriction and Hypotension Induced By Endothelin-1 in the Guinea Pig," British Journal of Pharmacology, 126:93-102 (January 1999)
Payen, et al., "Inhaled Nitric Oxide, Almitrine Infusion, or Their Coadministration as a Treatment of Severe Hypoxemic Focal Lung Lesions," Anesthesiology, 89:1157-65 (November 1998)
Samama et al., "Inhibition of Nitric Oxide Synthase Impairs Early Olfactory Associative Learning in Newborn Rats," Neurobiology of Learning and Memory, 71:219-31 (March 1999)
Sullivan et al., "Nitric Oxide Successfully used to treat Acute Chest Syndrome of Sickle Cell Disease in a Young Adolescent," Critical Care Medicine, 27:2563-8 (November 1999)

EXAMINER DATE CONSIDERED

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the annount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 80x 1450, Alexandria, VA 22313-1450. If you need assistance in completing the form, call 1-800-786-9199) and select option 2. "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 690. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 690. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 690. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 690. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 "EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 690. Draw line through citation if not in conformance and not considered. Include